IO Biotech Inc. (IOBT)
0.92
0.03 (3.37%)
At close: Apr 17, 2025, 9:53 AM
3.37% (1D)
| Bid | 0.86 |
| Market Cap | 60.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -95.49M |
| EPS (ttm) | -1.45 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -0.8 |
| Analyst | Buy |
| Ask | 0.91 |
| Volume | 11,028 |
| Avg. Volume (20D) | 169,763 |
| Open | 0.88 |
| Previous Close | 0.89 |
| Day's Range | 0.86 - 0.92 |
| 52-Week Range | 0.66 - 1.79 |
| Beta | 0.08 |
About IOBT
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and ne...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 5, 2021
Employees 80
Stock Exchange NASDAQ
Ticker Symbol IOBT
Website https://www.iobiotech.com
Analyst Forecast
According to 3 analyst ratings, the average rating for IOBT stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 986.96% from the latest price.
Stock Forecasts7 months ago
+3.22%
IO Biotech share are trading higher after announce...
Unlock content with
Pro Subscription
7 months ago
IO Biotech shares are trading lower after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.
